Major Research and Innovation Program (DIM) BioConvergence for Health – Call for Proposals 2026 / PhD Fellowships in Biotherapy, Bioproduction, and Synthetic Biology
BioConvergence for Health (BioConvS) is a "Major Research and Innovation Domain" (DIM) initiative of the Île-de-France Region, which aims to strengthen the communities working in synthetic biology, biotherapy, and bioproduction, to facilitate the transition from scientific excellence to innovation, and to position the Île-de-France region as a global leader in this field
BioConvS is led by Université Paris Cité in partnership with Sorbonne University, Institut Curie - PSL, Institut Micalis (INRAE, AgroParisTech, Université Paris Saclay), INSERM, Généthon, Génopole, and other partners. BioConvS brings together stakeholders from both the public and private sectors and receives up to €12.5 million in funding from the Île-de-France Region for the entire 2022-2026 funding period. More details about the BioConvS DIM can be found at: https://bioconvs.org/
About the call
This call for proposals will fund five doctoral fellowships for projects related to one of the thematic areas of the DIM BioConvS:
• Life sciences engineering and bioproduction • Development of proof-of-concept therapeutic approaches • New, high-throughput, and standardizable analytical methods • Digital tools or AI to improve data analysis or modeling in quality control and production methods • Ensuring inclusive, responsible, and sustainable bioconvergence
The application period runs from January 5 to May 4, 2026. Only doctoral theses supervised by at least two research teams (the second team may be a company) located in the Île-de-France region are eligible for this call.
Additional teams may participate in the project to provide complementary expertise, regardless of their location. However, teams outside the Île-de-France region will not receive funding.
As indicated above, start-ups and companies in the Île-de-France region may also be involved in the project, but they will not receive funding through this call. Involvement of a company in the project will be considered a positive factor.
Proposals must be written in English, but a French summary is required.
Loading... 
